Abstract

Regeneron Pharmaceuticals will report second-quarter 2026 results on July 30, 2026 Pre-Market, with investors watching revenue trajectory, gross margin durability, net profit trends, and adjusted EPS versus the company’s outlook and Street forecasts.

Market Forecast

Consensus points to Regeneron Pharmaceuticals delivering revenue of 3.82 billion US dollars for the current quarter, up 16.16% year over year, EBIT of 1.14 billion US dollars, and EPS of 10.32, with forecast EPS growth of 22.33% year over year. The market expects margin resilience this quarter, though explicit gross margin and net margin guidance are not provided; directionally, forecasts imply operating leverage accompanying top-line growth. The main business highlight remains product and collaboration revenue momentum driven by ophthalmology and immunology franchises, while management attention centers on execution in high-value biologics and launch curves. The most promising segment is expected to be collaboration revenue, supported by contributions around 1.90 billion US dollars last quarter and a favorable YoY trend as pipeline and partnered assets scale.

Last Quarter Review

In the previous quarter, Regeneron Pharmaceuticals reported revenue of 3.61 billion US dollars, a gross profit margin of 38.62%, GAAP net profit attributable to shareholders of 727.00 million US dollars with a net profit margin of 20.17%, and adjusted EPS of 9.47, reflecting a 19.03% revenue increase year over year and a 15.21% rise in adjusted EPS. A key highlight was EBIT of 1.04 billion US dollars, surpassing market expectations and delivering robust year-over-year growth of 41.74%. Main business revenues were led by collaboration at 1.90 billion US dollars, products at 1.53 billion US dollars, and other revenue at 171.20 million US dollars, underscoring diversified top-line drivers with collaboration as the largest contributor by mix.

Current Quarter Outlook (with major analytical insights)

Main commercial engine: Product and collaboration franchises

Regeneron Pharmaceuticals’ core revenue drivers this quarter remain its marketed biologics and partnered programs, which together underpin both growth and earnings quality. With consensus revenue at 3.82 billion US dollars and EPS at 10.32, the setup implies continued demand in ophthalmology and immunology, alongside steady milestone and profit-share flows from partners. The sequential cadence will be influenced by shipment timing and inventory normalization, yet the year-over-year expansion signals healthy underlying volume and pricing dynamics across leading indications. Operating cost discipline, coupled with a focus on high-margin biologics manufacturing, should support the earnings algorithm even as R&D investment stays elevated for pivotal programs.

Most promising growth vector: Collaboration revenue scaling

Collaboration revenue, which delivered 1.90 billion US dollars last quarter, appears positioned to remain a key growth lever given the near-term catalyst path in partnered assets and ongoing co-development economics. The 16.16% projected total revenue growth suggests collaboration-related milestones and profit-sharing could again be a notable positive swing factor versus the prior year. Execution risks include the timing of regulatory and clinical milestones, which can create lumpiness, but the breadth of partnered programs helps smooth volatility over multi-quarter horizons. As late-stage assets advance and commercialized therapies expand into additional geographies or indications, collaboration income can provide both diversification and incremental operating leverage.

Key stock-price swing factors this quarter

Margin trajectory and EPS delivery versus the 10.32 consensus will likely dominate the equity reaction, given investors’ sensitivity to gross margin mix and operating expense pacing. Any updates to launch curves in ophthalmology and immunology, including demand elasticity or competitive dynamics, could recalibrate revenue quality perceptions. Finally, visibility into the cadence of collaboration economics and any commentary on second-half milestone timing may influence how investors extrapolate the 16.16% growth profile into the remainder of 2026, affecting multiple and sentiment.

Analyst Opinions

Across recently published institutional commentaries and preview notes, the majority view is bullish, emphasizing sustained double-digit revenue growth, high-return biologics franchises, and improving operating leverage into the second half of 2026. Analysts highlight that the forecast 3.82 billion US dollars revenue and 10.32 EPS point to favorable demand trends and robust execution, with upside risk if collaboration receipts and product uptake exceed current run-rates. The constructive stance also reflects confidence that near-term milestone timing and manufacturing efficiency gains can support margins despite ongoing R&D intensity. Overall, the bullish camp frames the setup as skewed toward positive surprises on revenue and EPS, with attention centered on clarity around collaboration flows and updates that could enhance visibility for 2026 growth.